Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 3(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02993159Phase 2Completed

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Role: collaborator

NCT01143064Phase 3Completed

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

Role: lead

NCT03199963Phase 3Terminated

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

Role: lead

NCT02349386Phase 2Terminated

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

Role: lead

NCT03202186Phase 3Terminated

Study of Progesterone in Treatment of Vasomotor Symptoms

Role: lead

All 5 trials loaded